SCHEMBL6379342

SCHEMBL6379342

CCOC1=NCCCCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
NOS3 P29474 6/20 0.38
NOS1 P29475 6/20 0.38
NOS2 P35228 6/20 0.38
CYP2D6 P10635 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 2/20 0.34
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10892843 1.00 LMNA (0.40) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL10892852 1.00 LMNA (0.40) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL10895234 1.00 LMNA (0.40) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL5864938 0.98
SCHEMBL932427 0.91
SCHEMBL6379615 0.83 CYP2D6 (0.40) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL9639069 0.78 NOS3 (0.38) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL5865174 0.75 NOS3 (0.42) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL2382858 0.75 NOS3 (0.42) LMNANOS3NOS1NOS2CYP2D6
SCHEMBL5098524 0.75 NOS3 (0.42) LMNANOS3NOS1NOS2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395726-B1 REDUCTION OF CARBOXYL END GROUPS IN POLYESTER WITH LACTIM ETHERS AlliedSignal Inc. (US) 1992-07-15 EP claimed
US-11053206-B2 Hydrofluorocarboximidate and methods of making and using the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2021-07-06 US disclosed
US-20200207727-A1 HYDROFLUOROCARBOXIMIDATE AND METHODS OF MAKING AND USING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2020-07-02 US disclosed
EP-1076054-B1 PROCESS FOR PRODUCING ε-CAPROLACTAME SUMITOMO CHEMICAL CO (JP) 2005-08-03 EP disclosed
US-6344557-B1 REARRANGEMENT FROM 1-AZA-2-ALKOXY-1-CYCLOHEPTENE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-05 US disclosed
EP-1076054-A1 PROCESS FOR PRODUCING $g(e)-CAPROLACTAM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-14 EP disclosed
EP-0395726-B1 REDUCTION OF CARBOXYL END GROUPS IN POLYESTER WITH LACTIM ETHERS AlliedSignal Inc. (US) 1992-07-15 EP disclosed
EP-0395726-A1 REDUCTION OF CARBOXYL END GROUPS IN POLYESTER WITH LACTIM ETHERS. ALLIED SIGNAL INC (US) 1990-11-07 EP disclosed
WO-1989008160-A1 REDUCTION OF CARBOXYL END GROUPS IN POLYESTER WITH LACTIM ETHERS ALLIED-SIGNAL INC. (US) 1989-09-08 WO disclosed
US-4839124-A Reduction of carboxyl end groups in polyester fibers with lactim ethers ALLIED-SIGNAL INC. (US) 1989-06-13 US disclosed
US-4469653-A AS POLYMERIZATION CATALYSTS BASF AKTIENGESELLSCHAFT (DE) 1984-09-04 US disclosed
US-4404205-A CARDIOTONIC AGENTS; ANGINA PECTORIS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1983-09-13 US disclosed
EP-0069295-A1 Process for the manufacture of possibly cellular polyurethane or polyurethane-polyurea moulded articles BASF Aktiengesellschaft (DE) 1983-01-12 EP disclosed
US-4073783-A PENICILLINS PFIZER INC. (US) 1978-02-14 US disclosed
US-4052382-A 1-PHENYL-3-AZACARBOCYCLIC-UREAS STERLING DRUG INC. (US) 1977-10-04 US disclosed
US-4026938-A 1-Phenyl-3-azacarbocyclic-ureas STERLING DRUG INC. (US) 1977-05-31 US disclosed
US-4025506-A PENICILLINS PFIZER INC. (US) 1977-05-24 US disclosed
US-4025504-A PENICILLINS PFIZER INC. (US) 1977-05-24 US disclosed
US-3963748-A 1-Phenyl-3-azacarbocyclic-ureas STERLING DRUG INC. (US) 1976-06-15 US disclosed
US-3951952-A 6-(ALPHA-(AMIDINO-AND IMIDOYLAMINOALKANOYLAMINO)ARACYLAMINO)-PENICILLANIC ACIDS PFIZER INC. (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053206-B2 Hydrofluorocarboximidate and methods of making and using the same AFF1, AFF2, RFT1 LMNA 3798/4885NOS3 1070/4885NOS1 757/4885
US-20200207727-A1 HYDROFLUOROCARBOXIMIDATE AND METHODS OF MAKING AND USING THE SAME AFF1, AFF2, RFT1 LMNA 3798/4885NOS3 1070/4885NOS1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.